Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

TOMI Environmental Solutions, Inc. Heads to Austin, TX for AALAS 68th Annual National Meeting

Posted on: 09 Oct 17

BEVERLY HILLS, Calif., Oct. 09, 2017 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (“TOMI”) (OTCQX:TOMZ), a global decontamination company that specializes in disinfection/decontamination sales and services, including SteraMist™, a hydrogen peroxide-based mist/fog registered with the U.S. Environmental Protection Agency (“EPA”) for use as a hospital-healthcare disinfectant, will exhibit at the 68th annual national meeting of the American Association for Laboratory Animal Science (AALAS). This is the world’s largest gathering of professionals concerned with the production, care and use of animals in a laboratory setting.

TOMI has an excellent, proven reputation both domestically and internationally in a variety of industry sectors including BSL-4, Research, and Pharmaceutical Laboratories; Composting Facilities; and Vivariums. In 2016, a custom SteraMist™ built in system was designed and constructed in a vivarium at a leading cancer research institution in Boston, MA. 

SteraMist™ is an industry leader because of its proven efficacy against bacterial spores, including multiple drug resistant organisms, and viruses. This easy to implement and competitively priced technology allows facilities to maximize operational efficiencies and positions TOMI as a highly sought-after partner to those in the animal science laboratory industry.

Joe Lyons, TOMI’s sales director for this division, stated, “My team is excited to be at AALAS this year. We hope to use this conference as a platform to share this innovative technology with new companies who may not be aware of our multiple applications and reconnect with current partners to explore expanded use opportunities.”

The AALAS annual meeting will take place in Austin, TX (October 15-19th) at the Austin Convention Center. TOMI representatives in attendance will feature product demonstrations. To learn more about the company’s full range of products and services, visit Booth #1834.

About TOMI Environmental Solutions, Inc.
TOMI Environmental Solutions, Inc. (OTCQX:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform, which was invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense. BIT™ uses a low percentage Hydrogen Peroxide as its only active ingredient to produce a hydroxyl radical (OH ion), represented by the TOMI™ SteraMist™ brand of products, which produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI’s products are designed to service a broad spectrum of commercial structures including but not limited to hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities (when not in operation), military barracks, police and fire departments, and athletic facilities. TOMI’s products and services have also been used in single-family homes and multi-unit residences.

TOMI also develops training programs and application protocols for its clients and is a member in good standing of The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America and The Restoration Industry Association.

For additional information, please visit or contact us at

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.



Juliana deRosa
Executive Administrator


Last updated on: 10/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.